Julia Kopanz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julia Kopanz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Julia Katharina Mader
Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
4 shared publications - Mira G. P. Zuidgeest
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
4 shared publications Bart Lagerwaard
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
3 shared publicationsDiederick E Grobbee
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publicationsDietrich Tews
MVZ Diabeteszentrum Dr. Tews GmbH, Gelnhausen, Germany
2 shared publicationsJorien Veldwijk
Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by JMIR Publications Inc. in JMIR Nursing
- Vol. 9, e89687
Effects of a Digital Decision Support System on Diabetes Management in a Real-World Home Care Setting: Prospective Quasi-Experimental Feasibility and Implementation Study
Background: Older adults with diabetes are vulnerable, facing multimorbidity and challenges in reaching glycemic targets. When insulin therapy is required, limited knowledge of geriatric therapeutic goals often leads to regimens that increase the risk of hypoglycemia. Simplified approaches such as once-daily basal insulin are recommended, yet titration protocols and unclear regimens remain barriers in home care nursing. Digital decision support systems (DDSSs) such as GlucoTab address this gap by offering evidence-based titration guidance integrated into nursing workflows. DDSSs also strengthen nurse autonomy, which leads to improved care processes and better outcomes in home care settings. Objective: This study assessed the effects of a nurse-guided intervention including a DDSS for diabetes management in older adults with type 2 diabetes receiving home care nursing. Methods: The prospective quasi-experimental feasibility and implementation study was conducted using GlucoTab for diabetes management as part of a multicomponent intervention at 2 home care nursing sites. Nine adults with type 2 diabetes receiving insulin therapy were enrolled (n=5 women; mean age 77, SD 10 years; mean BMI 27.7, SD 4.7 kg/m 2 ; mean baseline hemoglobin A 1c 59.5, SD 12.8 mmol/mol). After receiving training, nurses implemented the DDSS, which integrates evidence-based diabetes management recommendations for home care and nursing workflows. Diabetes-related hospital admissions and glycemic outcomes were assessed before, during, and after implementation of the DDSS intervention. Results: Before implementation, 5 diabetes-related emergency admissions led to 4 hospitalizations, compared with none during implementation and 4 after implementation, mostly due to hyperglycemia. The median hospital stay was 9 (IQR 8-15) days (before and after implementation). Diabetes management shifted from predominantly premixed insulin therapy at baseline to basal insulin with or without bolus insulin during implementation. Diabetes-related home care visits decreased from 1.81 to 1.01 per day (before vs during implementation), and general practitioner contacts for insulin adjustments declined (19 before implementation vs 16 after implementation). Mean morning blood glucose decreased from 212 (SD 72) mg/dL to 162 (SD 42) mg/dL, and the proportion of measurements within the target range (70‐180 mg/dL) increased from 39.0% to 70.8% before vs during implementation. No incidence of hypoglycemia requiring third-party help was observed during implementation. Adherence of nurses to DDSS recommendations exceeded 94%. Conclusions: This study suggests that integrating a DDSS in a multicomponent intervention into home care nursing yielded longitudinal changes in diabetes outcomes. Emergency visits and hospitalizations were lower during implementation, no severe hypoglycemia was observed, glycemic control improved throughout the observation period, and therapy was simplified in routine care. Nursing visits decreased, suggesting potential improvements in care processes and resource use. High adherence and acceptance by nurses indicate feasibility and usability in home care practice. These findings align with evidence from hospitalized patients and telehealth studies, suggesting the potential for clinical, safety, and efficiency benefits.
- 24 September 2026
- Published by JMIR Publications Inc. in JMIR Nursing
- Vol. 9, e89687
Open AccessEffects of a Digital Decision Support System on Diabetes Management in a Real-World Home Care Setting: Prospective Quasi-Experimental Feasibility and Implementation Study
Background: Older adults with diabetes are vulnerable, facing multimorbidity and challenges in reaching glycemic targets. When insulin therapy is required, limited knowledge of geriatric therapeutic goals often leads to regimens that increase the risk of hypoglycemia. Simplified approaches such as once-daily basal insulin are recommended, yet titration protocols and unclear regimens remain barriers in home care nursing. Digital decision support systems (DDSSs) such as GlucoTab address this gap by offering evidence-based titration guidance integrated into nursing workflows. DDSSs also strengthen nurse autonomy, which leads to improved care processes and better outcomes in home care settings. Objective: This study assessed the effects of a nurse-guided intervention including a DDSS for diabetes management in older adults with type 2 diabetes receiving home care nursing. Methods: The prospective quasi-experimental feasibility and implementation study was conducted using GlucoTab for diabetes management as part of a multicomponent intervention at 2 home care nursing sites. Nine adults with type 2 diabetes receiving insulin therapy were enrolled (n=5 women; mean age 77, SD 10 years; mean BMI 27.7, SD 4.7 kg/m 2 ; mean baseline hemoglobin A 1c 59.5, SD 12.8 mmol/mol). After receiving training, nurses implemented the DDSS, which integrates evidence-based diabetes management recommendations for home care and nursing workflows. Diabetes-related hospital admissions and glycemic outcomes were assessed before, during, and after implementation of the DDSS intervention. Results: Before implementation, 5 diabetes-related emergency admissions led to 4 hospitalizations, compared with none during implementation and 4 after implementation, mostly due to hyperglycemia. The median hospital stay was 9 (IQR 8-15) days (before and after implementation). Diabetes management shifted from predominantly premixed insulin therapy at baseline to basal insulin with or without bolus insulin during implementation. Diabetes-related home care visits decreased from 1.81 to 1.01 per day (before vs during implementation), and general practitioner contacts for insulin adjustments declined (19 before implementation vs 16 after implementation). Mean morning blood glucose decreased from 212 (SD 72) mg/dL to 162 (SD 42) mg/dL, and the proportion of measurements within the target range (70‐180 mg/dL) increased from 39.0% to 70.8% before vs during implementation. No incidence of hypoglycemia requiring third-party help was observed during implementation. Adherence of nurses to DDSS recommendations exceeded 94%. Conclusions: This study suggests that integrating a DDSS in a multicomponent intervention into home care nursing yielded longitudinal changes in diabetes outcomes. Emergency visits and hospitalizations were lower during implementation, no severe hypoglycemia was observed, glycemic control improved throughout the observation period, and therapy was simplified in routine care. Nursing visits decreased, suggesting potential improvements in care processes and resource use. High adherence and acceptance by nurses indicate feasibility and usability in home care practice. These findings align with evidence from hospitalized patients and telehealth studies, suggesting the potential for clinical, safety, and efficiency benefits.
- Open Access
Do all individuals with type 2 diabetes mellitus prefer decentralisation in clinical trials? Findings from a discrete choice experiment
Objectives: To explore differences in preferences for participation in trials with varying degrees of decentralisation among individuals with type 2 diabetes mellitus (T2DM) and to show how personal, disease specific, digital and trial experience factors influence these preferences as well as impact potential trial participation rates. Design: A discrete choice experiment was conducted, including 16 choice tasks, with each two trial options and an opt-out. Setting: Preference data was collected in the Netherlands between July 2023 and July 2024. Participants: A total of 276 individuals with T2DM aged ≥18 years took part in the study. Outcome measures: Trial options comprised six attributes: contact with the study team, activities to perform yourself, use of digital technologies, number of scheduled contacts, trial duration, safety and efficacy of the drug. Preference heterogeneity was explored using a latent class analysis. Results: Four classes were identified displaying differences in preferences for trial designs. Younger female participants were more likely to have a strong preference for decentralised trials in any form. Two different classes of elderly participants were identified: elderly males who were more likely to accept any trial design including decentralisation versus elderly who were more likely to be averse to participation in all trials. The latter class showed an increase in participation probability for a home-based trial including video consultation, but still was not very likely to join. Conclusions: Decentralisation in trials was overall preferred over site-based trials, but variation in preferences was identified and associated with age and gender. This may impact the choice for decentralisation in trials, especially since women and the elderly are often under-represented in trials. Understanding patient preferences may help to overcome participation challenges and to increase diversity in future trials.
Open AccessDo all individuals with type 2 diabetes mellitus prefer decentralisation in clinical trials? Findings from a discrete choice experiment
Objectives: To explore differences in preferences for participation in trials with varying degrees of decentralisation among individuals with type 2 diabetes mellitus (T2DM) and to show how personal, disease specific, digital and trial experience factors influence these preferences as well as impact potential trial participation rates. Design: A discrete choice experiment was conducted, including 16 choice tasks, with each two trial options and an opt-out. Setting: Preference data was collected in the Netherlands between July 2023 and July 2024. Participants: A total of 276 individuals with T2DM aged ≥18 years took part in the study. Outcome measures: Trial options comprised six attributes: contact with the study team, activities to perform yourself, use of digital technologies, number of scheduled contacts, trial duration, safety and efficacy of the drug. Preference heterogeneity was explored using a latent class analysis. Results: Four classes were identified displaying differences in preferences for trial designs. Younger female participants were more likely to have a strong preference for decentralised trials in any form. Two different classes of elderly participants were identified: elderly males who were more likely to accept any trial design including decentralisation versus elderly who were more likely to be averse to participation in all trials. The latter class showed an increase in participation probability for a home-based trial including video consultation, but still was not very likely to join. Conclusions: Decentralisation in trials was overall preferred over site-based trials, but variation in preferences was identified and associated with age and gender. This may impact the choice for decentralisation in trials, especially since women and the elderly are often under-represented in trials. Understanding patient preferences may help to overcome participation challenges and to increase diversity in future trials.
- Open Access
Do people prefer to take part in a clinical trial from home or come to site? A discrete choice experiment in type 2 diabetes mellitus
Objectives: To determine what drives participation in clinical trials with decentralised elements and to estimate trial participation probabilities for trials with different degrees of decentralisation. Design: Patient preference study using a discrete choice experiment. Setting: Recruitment in primary, secondary, tertiary care and other settings in the Netherlands (NL), Austria (AT) and Germany (DE). Participants: People with type 2 diabetes mellitus (T2DM) aged ≥18 years. A total of 787 people (NL n=276, AT n=265, DE n=246) participated in the study. Main outcome measures: Preferences for participation in clinical trials with different options for location and type of contact with the study team, activities to perform by participant, use of digital technologies by participant, number of scheduled contacts, trial duration, known safety and efficacy of the drug. Results: How much was known about the safety and efficacy of the drug was the most important element in the decision whether to participate in a clinical trial in all countries. The trial duration, location and type of contact with the study team, and number of scheduled contacts were other important elements. Participation probabilities for hypothetical trial scenarios differed between countries, with the highest rates for a decentralised trial involving video contact (NL: 89%; AT: 99%; DE: 84%). Conclusions: People with T2DM prefer to take part in clinical trials with decentralised approaches. Information on preferences can help trialists and protocol developers to design and plan future trials that integrate patients’ needs and thus reduce barriers to participation.
Open AccessDo people prefer to take part in a clinical trial from home or come to site? A discrete choice experiment in type 2 diabetes mellitus
Objectives: To determine what drives participation in clinical trials with decentralised elements and to estimate trial participation probabilities for trials with different degrees of decentralisation. Design: Patient preference study using a discrete choice experiment. Setting: Recruitment in primary, secondary, tertiary care and other settings in the Netherlands (NL), Austria (AT) and Germany (DE). Participants: People with type 2 diabetes mellitus (T2DM) aged ≥18 years. A total of 787 people (NL n=276, AT n=265, DE n=246) participated in the study. Main outcome measures: Preferences for participation in clinical trials with different options for location and type of contact with the study team, activities to perform by participant, use of digital technologies by participant, number of scheduled contacts, trial duration, known safety and efficacy of the drug. Results: How much was known about the safety and efficacy of the drug was the most important element in the decision whether to participate in a clinical trial in all countries. The trial duration, location and type of contact with the study team, and number of scheduled contacts were other important elements. Participation probabilities for hypothetical trial scenarios differed between countries, with the highest rates for a decentralised trial involving video contact (NL: 89%; AT: 99%; DE: 84%). Conclusions: People with T2DM prefer to take part in clinical trials with decentralised approaches. Information on preferences can help trialists and protocol developers to design and plan future trials that integrate patients’ needs and thus reduce barriers to participation.
- Open Access
- 1 September 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (1) , 280-290
Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
Aims: The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus. Methods: A total of 226 clinical trial protocols identified from the ClinicalTrials.gov database were systematically reviewed by five researchers. Data on trial and PE characteristics were extracted, including frequency and timing, purpose, elements and conduct of PE. Results: A total of 211 protocols (59% phase 3, 72% two‐arm trials) were reviewed. Of these, 190 protocols mentioned a PE, and by distinguishing between different types of PE, a total of 241 PEs were assessed. Of the 190 protocols, 65% of protocols explicitly documented the purpose(s) for conducting a PE. PE was most often explicitly documented to identify adverse events (40%), followed by assessment of trial endpoints (33%), eligibility (21%), overall health status (3%) and characterization of the study population (1%). Sixty per cent of PEs described what was to be examined, and 8% specified how the PE should be conducted. Conclusions: Protocols often lacked information on the purpose, elements and conduct of the PE, which may negatively impact the consistency of clinical trials. With the purpose of PE being often not explicitly stated, it can be questioned whether a PE is needed in every clinical trial or if it is performed as a matter of routine. Future research is needed to investigate whether PE is always necessary in a clinical trial and to explore opportunities for PE in clinical trial innovations including decentralization.
- 1 September 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (1) , 280-290
Open AccessWhy and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
Aims: The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus. Methods: A total of 226 clinical trial protocols identified from the ClinicalTrials.gov database were systematically reviewed by five researchers. Data on trial and PE characteristics were extracted, including frequency and timing, purpose, elements and conduct of PE. Results: A total of 211 protocols (59% phase 3, 72% two‐arm trials) were reviewed. Of these, 190 protocols mentioned a PE, and by distinguishing between different types of PE, a total of 241 PEs were assessed. Of the 190 protocols, 65% of protocols explicitly documented the purpose(s) for conducting a PE. PE was most often explicitly documented to identify adverse events (40%), followed by assessment of trial endpoints (33%), eligibility (21%), overall health status (3%) and characterization of the study population (1%). Sixty per cent of PEs described what was to be examined, and 8% specified how the PE should be conducted. Conclusions: Protocols often lacked information on the purpose, elements and conduct of the PE, which may negatively impact the consistency of clinical trials. With the purpose of PE being often not explicitly stated, it can be questioned whether a PE is needed in every clinical trial or if it is performed as a matter of routine. Future research is needed to investigate whether PE is always necessary in a clinical trial and to explore opportunities for PE in clinical trial innovations including decentralization.
- Open Access
- 22 November 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (11) , e70070
What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?
Decentralized clinical trials (DCTs), in which all or part of the trial activities are moved to the participants' immediate surroundings, promise to improve trial conduct. However, no evidence is available on what motivates people to participate in DCTs. Our aim was to determine the drivers and perceptions for participation in clinical trials with different decentralization levels in persons with type 2 diabetes mellitus. Five focus groups were conducted utilizing the nominal group technique in the Netherlands (n = 1), Germany (n = 1), and Austria (n = 3) with four to six participants per group. The focus groups were analyzed using thematic analysis. Of the 26 participants (10 females, median age: 66 years [IQR: 62–72]) 42% had previously participated in a trial, and almost all had internet access at home (96%). A total of seven main themes regarding participation in clinical trials (location, time investment, contact with healthcare professionals (HCPs), digital technologies, data collection, perceived risk, and motivation) were identified, of which a total of 20 drivers emerged. Perceptions regarding trial participation differed widely among participants, and individual preferences influenced which drivers were considered more important by participants. Flexibility of location and time spent on the trial were identified as the most motivating factors for participation in DCTs. Some drivers, such as digital infrastructure, digital literacy, home visits, personal interaction, and relationship with HCPs were perceived as both enablers and barriers, depending on personal preferences. However, most of the potential barriers regarding DCTs may be resolved by addressing them in the design of future DCTs.
- 22 November 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (11) , e70070
Open AccessWhat motivates people with type 2 diabetes mellitus to participate in clinical trials from home?
Decentralized clinical trials (DCTs), in which all or part of the trial activities are moved to the participants' immediate surroundings, promise to improve trial conduct. However, no evidence is available on what motivates people to participate in DCTs. Our aim was to determine the drivers and perceptions for participation in clinical trials with different decentralization levels in persons with type 2 diabetes mellitus. Five focus groups were conducted utilizing the nominal group technique in the Netherlands (n = 1), Germany (n = 1), and Austria (n = 3) with four to six participants per group. The focus groups were analyzed using thematic analysis. Of the 26 participants (10 females, median age: 66 years [IQR: 62–72]) 42% had previously participated in a trial, and almost all had internet access at home (96%). A total of seven main themes regarding participation in clinical trials (location, time investment, contact with healthcare professionals (HCPs), digital technologies, data collection, perceived risk, and motivation) were identified, of which a total of 20 drivers emerged. Perceptions regarding trial participation differed widely among participants, and individual preferences influenced which drivers were considered more important by participants. Flexibility of location and time spent on the trial were identified as the most motivating factors for participation in DCTs. Some drivers, such as digital infrastructure, digital literacy, home visits, personal interaction, and relationship with HCPs were perceived as both enablers and barriers, depending on personal preferences. However, most of the potential barriers regarding DCTs may be resolved by addressing them in the design of future DCTs.
- Open Access
Evaluation of an implemented new insulin chart to improve quality and safety of diabetes care in a large university hospital: a follow-up study
Objectives To evaluate structure, documentation, treatment quality of a new implemented standardised insulin chart in adult medical inpatient wards at a university hospital. Design A before–after study (3 to 5 months after implementation) was used to compare the quality of old versus new insulin charts. Setting University Hospital Graz, Austria. Participants Healthcare professionals (n=237) were questioned regarding structure quality of blank insulin charts. Interventions A new standardised insulin chart was implemented and healthcare professionals were trained regarding features of this chart. Data from insulinised inpatients were evaluated regarding documentation and treatment quality of filled-in insulin charts (n=108 old insulin charts vs n=100 new insulin charts). Main outcomes and measures The primary endpoint was documentation error for insulin administration. Results Healthcare professionals reported an improved structure quality of the new insulin chart with a Likert type response scale increase in all nine items. Documentation errors for insulin administration (primary endpoint) occurred more often on old than new insulin charts (77% vs 5%, pConclusions The implementation of a structured documentation form together with training measures for healthcare professionals led to less documentation errors and safe management of glycaemic control in hospitalised patients in a short time follow-up. A rollout at further medical wards is recommended, and sustainability in the long-term has to be demonstrated.
Open AccessEvaluation of an implemented new insulin chart to improve quality and safety of diabetes care in a large university hospital: a follow-up study
Objectives To evaluate structure, documentation, treatment quality of a new implemented standardised insulin chart in adult medical inpatient wards at a university hospital. Design A before–after study (3 to 5 months after implementation) was used to compare the quality of old versus new insulin charts. Setting University Hospital Graz, Austria. Participants Healthcare professionals (n=237) were questioned regarding structure quality of blank insulin charts. Interventions A new standardised insulin chart was implemented and healthcare professionals were trained regarding features of this chart. Data from insulinised inpatients were evaluated regarding documentation and treatment quality of filled-in insulin charts (n=108 old insulin charts vs n=100 new insulin charts). Main outcomes and measures The primary endpoint was documentation error for insulin administration. Results Healthcare professionals reported an improved structure quality of the new insulin chart with a Likert type response scale increase in all nine items. Documentation errors for insulin administration (primary endpoint) occurred more often on old than new insulin charts (77% vs 5%, pConclusions The implementation of a structured documentation form together with training measures for healthcare professionals led to less documentation errors and safe management of glycaemic control in hospitalised patients in a short time follow-up. A rollout at further medical wards is recommended, and sustainability in the long-term has to be demonstrated.